Santen Pharmaceutical Asia Pte. Ltd.
Quick facts
Marketed products
- Eybelis ophthalmic solution 0.002% · Ophthalmology
Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: